$569 Million is the total value of Aisling Capital LLC's 22 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CEMP | CEMPRA INC | $61,055,000 | -19.0% | 2,193,060 | 0.0% | 10.73% | -4.3% | |
| LOXO | LOXO ONCOLOGY INC | $60,350,000 | -3.0% | 3,452,493 | 0.0% | 10.61% | +14.5% | |
| ESPR | ESPERION THERAPEUTICS INC. | $38,620,000 | -71.1% | 1,637,125 | 0.0% | 6.79% | -65.9% | |
| ADMA | ADMA BIOLOGICS INC | $30,164,000 | -9.7% | 3,608,171 | 0.0% | 5.30% | +6.6% | |
| VSAR | VERSARTIS INC | $26,283,000 | -24.2% | 2,279,568 | 0.0% | 4.62% | -10.5% | |
| DERM | DERMIRA INC | $25,722,000 | +33.0% | 1,102,046 | 0.0% | 4.52% | +57.0% | |
| TTOO | T2 BIOSYSTEMS INC | $22,104,000 | -46.0% | 2,523,300 | 0.0% | 3.89% | -36.3% | |
| AGRX | AGILE THERAPEUTICS INC | $20,111,000 | -21.5% | 2,983,797 | 0.0% | 3.54% | -7.4% | |
| TRXC | TRANSENTERIX INC. | $18,839,000 | -24.7% | 8,335,819 | 0.0% | 3.31% | -11.1% | |
| CTLT | CATALENT INC | $17,391,000 | -17.2% | 715,673 | 0.0% | 3.06% | -2.2% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $12,971,000 | -26.3% | 682,680 | 0.0% | 2.28% | -13.0% | |
| XENT | INTERSECT ENT INC | $8,190,000 | -18.3% | 350,000 | 0.0% | 1.44% | -3.5% | |
| PTX | PERNIX THERAPEUTICS HLDGS IN | $6,352,000 | -46.6% | 2,010,000 | 0.0% | 1.12% | -37.0% | |
| EVAR | LOMBARD MED INC | $3,164,000 | -18.9% | 886,363 | 0.0% | 0.56% | -4.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.